|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| GlaxoSmithKline plc: Company Profile |
|
|
|
|
€ 280,00 |
Editeur
: |
Koncept Analytics |
Langue
: |
Anglais |
Date de publication : |
Juin 2008 |
Taille du document : |
25 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (2) |
|
|
|
| 67 pages | Janvier 2005 | Anglais
|
|
|
| Main
focus: |
financials
|
| Research
focus: |
market definition,competition analysis |
| Geographic
focus: |
usa |
| |
|
|
|
|
| 45 pages | Avril 2004 | Anglais
|
|
|
| Main
focus: |
financials,financial analytics,wifi
|
| Research
focus: |
competition analysis,industry structure, |
| Geographic
focus: |
usa,france,united kingdom,germany |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
The Drug Delivery Outlook to 2005 150 pages | Février 1999 |
Strategic overview : defines and values the market covered in the report, provides a macro analysis of the reasons why the drug delivery sector is growing at current rates and predicts how the c |
795,00 €
|
| |
| |
Healthcare In Southern Ireland 40 pages | Mai 2000 |
The Republic Of Ireland Presentation Includes:- The Structure Of The Health Service In The Republic Of Ireland- Capital Expenditure On Health Care In The Republic Of Ireland- Number Of Publicly Funded |
327,00 €
|
| |
| |
Global Pharmaceutical: a market, company and disease analysis 150 pages | Octobre 1998 |
What will drive pharmaceutical market growth into the 21st Century? What are the key challenges facing pharmaceutical manufacturers? Who are the market leaders in each sector? What strategies ar |
795,00 €
|
| |
| |
The Diagnostics Outlook to 2005 130 pages | Février 1999 |
Diagnostic market : The current in vitro diagnostic (IVD) market is discussed, identifying how the market can be segmented according to country, end user, clinical speciality and disease area.
|
795,00 €
|
| |
| |
Healthcare: Germany 106 pages | Octobre 2000 |
Compare the changes in expenditure between the different healthcare sectors in Germany · Understand the main factors affecting demand for healthcare services in Germany · Examine the |
578,54 €
|
| |
| |
Bridging the Pharmaceutical Earnings gap: Key Strategies in the race for growth 173 pages | Mars 2000 |
The favorable climate of the pharmaceutical sector has changed radically over the past ten years. Where once near unrestricted revenue expansion existed, external pressures now act in unison |
955,00 €
|
| |
| |
Maximising the Drug Lifecycle 102 pages | Août 2001 |
Up to $100bn of the 2000 pharmaceutical market, including blockbuster drugs with combined sales of $34bn will be exposed to generic competition by 2005.Maximising The Drug Lifecycle provides a detaile |
955,00 €
|
| |
| |
Chinese Markets for Pharmaceuticals 225 pages | Janvier 2002 |
China's demand for pharmaceuticals has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic |
2 835,00 €
|
| |
| |
The Pharmaceutical Distribution Outlook 1998-2008 165 pages | Octobre 1998 |
Industry growth and consolidation means that pharmaceutical manufacturers are no longer geographically limited in their operations and now market their products globally, creating a vast commercia |
795,00 €
|
| |
| |
Healthcare In Scotland 52 pages | Mai 2000 |
The Scottish Presentation Includes:- The Structure Of The NHS In Scotland- The Funding Of The NHS In Scotland- Distribution Of The NHS Budget In Scotland- Segmentation Of Expenditure - Total Capital E |
327,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| GlaxoSmithKline plc: Company Profile |
|
|
This company profile offers a comprehensive analysis of the organization, its business segments, and competitors. It analyzes the business and marketing strategies adopted by the company, to gain a competitive edge in the industry. The profile also evaluates the strengths of the company and the opportunities present in the market.
This profile is of immense help to management consultants, analysts, market research organizations and corporate advisors.
The objective and scope of various sections of our company profile has been discussed below.
Company Summary This section presents the key facts & figures, business description, products & services offered and corporate timeline of the company.
Company Analysis It involves analysis of the company at three levels – segments, organizational structure and ownership composition. Both business and geographic segments are analyzed alongwith their recent financial performance. It further discusses the major subsidiaries of the company and the recent merger & acquisitions. Business Developments This section examines the significant developments that have taken place in the company. It is a form of news analysis where the most critical company news is discussed.
Discussion of Business Strategies This section talks about the current and future strategies of the company. All business, marketing, financial and organizational strategies are discussed here.
SWOT Our SWOT Analysis is a valuable step in assessing your company's strengths, weaknesses, opportunities, and threats. It offers powerful insight into the critical issues affecting a business. Financial Performance It discusses the most recent financials of the company and also compares the historical sales & income figures with the current and projected figures. The objective is to evaluate the financial health of the company. The analyst opinion and stock performance help us in evaluating the performance of the company from an investor’s viewpoint.
Competition Synopsis This section compares the company with its peer group. The comparable analysis and stock movement are aimed at giving an overview of the competitive landscape in the industry and the company’s positioning in its peer group.
|
|
1. Company Summary
1.1 Company At-a-Glance 1.2 Business Description 1.3 History 1.4 Products/Services
2. Company Analysis
2.1 Segment Analysis 2.1.1 By Business Segments 2.1.2 By Geographic Segments
2.2 Management and Operating Structure 2.2.1 Organizational Structure 2.2.2 Key Executives - Hierarchy Chart 2.2.3 Executive Bios
2.3 Ownership Composition 2.4 Subsidiaries 2.5 Mergers and Acquisitions
3. Business Developments – A Review
4. Discussion of Business Strategies
5. SWOT 5.1 Strengths 5.2 Weaknesses 5.3 Opportunities 5.4 Threats
6. Financial Performance
6.1 Financial Highlights 6.2 Sales Performance 6.3 Earnings Analysis 6.4 Ratio Comparison 6.5 Stock Analysis 6.6 Management Outlook 6.7 Analyst Opinion
7. Competition Synopsis
7.1 Competitive Landscape 7.2 Key Competitors 7.3 Competitors At-a-Glance 7.4 Sales & Earnings Comparison 7.5 Stock Performance Comparison 7.6 Market Capitalization
Tables/Charts
1. Company At-a-Glance 2. Ownership Composition 3. Organizational Structure 4. Key Executives – Hierarchy Chart 5. M&A Timeline 6. Major Subsidiaries 7. Key Financials 8. Revenue by Business Segments 9. Revenue by Geographic Segments 10. Sales & Earnings Growth 11. Key Ratios 12. Stock Performance Chart 13. Competitors At-a-Glance 14. Sales & Earnings Growth: Performance Comparison 15. Comparative Stock Performance 16. Market Capitalization 17. SWOT Chart
|
|
|
PPLSEN
|
|
|
|
|